Evidence map›Paper›PMID 42413918›Full record

ArticleBritish journal of haematology2026

Real-world prevalence and prognostic significance of hepatotoxicity after chimeric antigen receptor T-cell therapy.

Julius Hollnberger, Tim Richardson, Philipp Gödel, Joshua Leutiger, Jan Christoph Schumacher, Sophie Schiestel, Benedict Allhoff, Christof Scheid, Udo Holtick, Christoph Neumann-Haefelin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Julius HollnbergerDepartment of Gastroenterology and Hepatology, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-6340-8685
Tim RichardsonDepartment 1 of Internal Medicine, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Philipp GödelDepartment 1 of Internal Medicine, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Joshua LeutigerDepartment of Gastroenterology and Hepatology, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Jan Christoph SchumacherDepartment of Gastroenterology and Hepatology, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-8817-2947
Sophie SchiestelDepartment of Gastroenterology and Hepatology, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Benedict AllhoffDepartment of Gastroenterology and Hepatology, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Christof ScheidDepartment 1 of Internal Medicine, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Udo HoltickDepartment 1 of Internal Medicine, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Christoph Neumann-HaefelinDepartment of Gastroenterology and Hepatology, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
Gabriel AlloDepartment of Gastroenterology and Hepatology, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-7568-7431
Philipp KasperDepartment of Gastroenterology and Hepatology, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this real-world cohort of 231 patients receiving chimeric antigen receptor (CAR) T-cell therapy, hepatotoxicity occurred in 58% of patients, predominantly as transient transaminase elevations, and was not associated with impaired 12-month overall survival (adjusted hazard ratio [HR] 1.18, 95% confidence interval [CI] 0.71-1.94).

Indexed as

Chemical and Drug Induced Liver InjuryImmunotherapy, AdoptiveReceptors, Chimeric AntigenAdultAgedFemaleHumansMaleMiddle AgedPrevalencePrognosisReceptors, Chimeric AntigenCAR T‐cell therapycytokine release syndromehepatotoxicityliver function testsreal‐world study

Identifiers

PMID42413918
PMCPMC13570130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.